Depression: all studies (page 24) - The Consciousness Library

Ketamine and Esketamine in Depression: Current Evidence on Mechanisms, Efficacy, Safety and Clinical Use – A Review

Journal of Education, Health and Sport June 22, 2026 Urszula Szuleta, Wiktoria Zawada, Krystian Kaczmarek et al.

Introduction and purpose. Major depressive disorder is a serious clinical problem. Current treatments are often unsuccessful, and many patients do not achieve full remission. In a reanalysis of the STAR*D study, the cumulative remission rate after up to four treatment steps was about 41%, which highlights the limitations of currently available antidepressant strategies[1]. In recent years,...

DOI: 10.12775/jehs.2026.93.72419 Ketamine Major depressive disorder Antidepressant Depression economics +6

Treatment-Resistant Depression: A Psychiatry Perspective on Pathophysiological Mechanisms, Biomarkers, and Novel Therapeutic Frontiers

INNOVAPATH June 22, 2026 Muhammad Bilal Akram, Ali Sher, Areena Fatima et al.

Treatment-resistant depression (TRD) represents a major clinical and public health challenge, affecting a substantial proportion of patients with major depressive disorder who fail to achieve remission despite adequate pharmacotherapy. Emerging evidence suggests that TRD is a heterogeneous condition driven by complex interactions among neurobiological, inflammatory, and psychosocial factors....

DOI: 10.63501/54mphj57 Major depressive disorder Perspective graphical Psychosocial Identification biology +7

Effects of Esketamine on EEG temporal dynamics in patients with depression

UNC Libraries June 21, 2026 Verina Guirguis

Esketamine is an effective rapid-acting pharmacological intervention for treatment-resistant depression. However, the temporal dynamics of underlying brain networks associated with the improvement of depressive symptoms remain elusive. This observational study seeks to delineate alteration in network activity within 90 minutes of nasal Esketamine administration, with a focus on exploring its...

DOI: 10.17615/b350-9s23 Major depressive disorder Anxiety Treatment-resistant depression Depression economics +9

Efficacy of Yoga in Enhancing the Mental Health of Women with Postpartum Depression: A Comprehensive Review

Indian Journal of YOGA Exercise & Sport Science and Physical Education June 20, 2026 Kusum Sharma, Dr. Abhishek Bhardwaj

Aim of the study: This comprehensive review aims to compile the corpus of research on the therapeutic effectiveness of yoga in enhancing the mental health and well-being of new mothers with symptoms of postpartum depression. The present study is an attempt to look at how yoga practice in the postnatal period after delivery of the baby can help in reducing the symptoms of postpartum depression...

DOI: 10.58914/ijyesspe.2026-11.1.6

Association of Esketamine use with mortality and clinical outcomes in patients with cancer-related depression: A target trial emulation.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2026 Jen-Ping Chen, Chih-Wei Hsu, Yi-Ya Fang et al.

Although esketamine shows efficacy for treatment-resistant depression, its potential effectiveness in cancer-related depression (CRD) has not been well-established. We therefore evaluated the real-world effectiveness and safety of esketamine in CRD using a target trial emulation framework based on anonymized electronic health records from the TriNetX network. Adults aged 18-74 years with CRD...

DOI: 10.1016/j.pnpbp.2026.111764 Full text Esketamine Cancer-related depression Mortality Target trial emulation

Comparative network pharmacology analysis of ketamine and xanomeline in major depressive disorder: Shared and distinct molecular mechanisms.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2026 Xin Ding, Kenji Hashimoto, Jian-Jun Yang

Major depressive disorder (MDD) is a leading cause of disability worldwide, and currently available antidepressants remain limited by delayed onset of action, incomplete response, and adverse effects. Ketamine is a rapid-acting antidepressant, whereas xanomeline, an M1/M4 muscarinic receptor agonist, may represent a mechanistically distinct non-monoaminergic strategy. However, the molecular...

DOI: 10.1016/j.pnpbp.2026.111727 Full text Ketamine Major depressive disorder Molecular docking Network pharmacology +1

Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence

Annals of Medicine and Surgery June 18, 2026 Astrit Sabani, Adnan Khatak

Treatment-resistant depression (TRD) remains a major clinical challenge and is typically defined as the persistence of depressive symptoms despite at least two adequate antidepressant trials. Individuals with TRD experience substantial morbidity, impaired functioning, and elevated suicide risk, highlighting the need for therapeutic strategies beyond incremental refinements of conventional...

DOI: 10.1097/ms9.0000000000005244 Major depressive disorder Treatment-resistant depression Electroconvulsive therapy Dosing +10

Preliminary efficacy of a self-guided mobile intervention for reducing stress in depression: A randomized controlled crossover trial.

Journal of Affective Disorders June 17, 2026 Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin et al.

Stress worsens clinical outcomes in patients with major depressive disorder (MDD); however, timely accessible stress management tools remain limited. Digital interventions offer scalable adjunctive solutions early during pharmacological treatment. In this multicenter, assessor-blinded, randomized controlled crossover pilot trial, we conducted a preliminary evaluation of the short-term efficacy...

DOI: 10.1016/j.jad.2026.122143 Full text Mindfulness Major depressive disorder Humans Treatment outcome +11

Mindfulness in schools for internal migrant children at risk of anxiety and depression: A randomized trial.

Social Science & Medicine June 17, 2026 Shuang Lu, Renhui Lyu, Xiaolu Dai et al.

Rapid urbanization and unequal urban-rural development have driven large-scale internal migration in low- and middle-income countries, placing internal migrant children at increased risk for psychological distress and sociocultural marginalization. Although schools are critical settings for prevention, targeted interventions that support migrant students' psychological ("feeling well") and...

DOI: 10.1016/j.socscimed.2026.119511 Depression Anxiety Mindfulness Humans +9

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States.

Journal of Medical Internet Research June 17, 2026 Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...

DOI: 10.2196/92647 Full text